Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Weight Loss Intervention With Semaglutide in Patients With Estrogen Receptor-positive Breast Cancer (WISPER): A Phase II, Randomized, Open-label, Single-center, Delayed-start Feasibility Trial of Glucagon-like Peptide-1 Receptor Agonist Therapy During Adjuvant Endocrine Therapy.

NCT07909889 is registered in ClinicalTrials.gov with Aarhus University Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07909889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Weight Loss Intervention With Semaglutide in Patients With Estrogen Receptor-positive Breast Cancer (WISPER): A Phase II, Randomized, Open-label, Single-center, Delayed-start Feasibility Trial of Glucagon-like Peptide-1 Receptor Agonist Therapy During Adjuvant Endocrine Therapy.
Lead sponsor
Aarhus University Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
September 30, 2029
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (early breast cancer), obesity

Arms

As registered; 2 arms.

  • Immediate-start semaglutide ExperimentalSemaglutide (Wegovy®)

    Participants receive semaglutide once weekly for 26 weeks starting at randomization, followed by 26 weeks of post-treatment observation. Usual adjuvant endocrine therapy, routine oncology follow-up and standardized written guidance on diet and physical activity continue throughout participation.

  • Delayed-start semaglutide ExperimentalSemaglutide (Wegovy®)

    Participants receive standard care alone for the first 26 weeks after randomization, then semaglutide once weekly for 26 weeks, followed by 26 weeks of post-treatment observation. Standard care comprises usual adjuvant endocrine therapy, routine oncology follow-up and standardized written guidance on diet and physical activity. Total follow-up is 78 weeks from randomization.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Completion of the 26-week semaglutide treatment phase meeting all composite feasibility criteria At completion of 26 weeks of semaglutide treatment: trial week 26 in Arm A and trial week 52 in Arm B.

    Percentage of participants who complete the assigned 26-week treatment phase while meeting all three criteria: no permanent discontinuation of prescribed adjuvant endocrine therapy; no permanent discontinuation of semaglutide; and administration of at least 21 of 26 planned weekly semaglutide injections. Endocrine therapy continuation is assessed from prescription records and self-reported intake; semaglutide adherence is assessed from electronic dosing diaries with pen reconciliation. The proportion will be reported with a 95% confidence interval.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Semaglutide 41 Orange Book patentsPatent cliff February 17, 2041 (Orange Book patent)
    • US 11318191; expires February 17, 2041; assignee Novo Nordisk A S
    • US 11478533; expires May 13, 2040; assignee Novo Nordisk A S
    • US 11833248; expires February 1, 2039; assignee Novo Nordisk A S
    • US 12396953; expires February 1, 2039; assignee Novo Nordisk A S
    • US 12029779; expires October 10, 2038; assignee Novo Nordisk A S
    • +36 more patents

Lead sponsor's other trials

Aarhus University Hospital, most recent start first.

Similar trials

Same condition (Weight Loss) and phase, most recent start first.